Clinical Trials
COAST
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).
Overview
A 2-year Phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Cerulea on +61 3 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Dr Thanh Nguyen
A 2-year Phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Cerulea on +61 3 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.